What is Leerink Partnrs’ Estimate for CGEM Q1 Earnings?

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Cullinan Therapeutics in a report released on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of ($0.74) per share for the quarter. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.12) per share. Leerink Partnrs also issued estimates for Cullinan Therapeutics’ Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.84) EPS and Q4 2025 earnings at ($0.88) EPS.

Cullinan Therapeutics (NASDAQ:CGEM) last posted its earnings results on Thursday, November 7th. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.09.

CGEM has been the topic of a number of other research reports. UBS Group initiated coverage on Cullinan Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $30.00 target price on the stock. HC Wainwright lifted their target price on Cullinan Therapeutics from $28.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $32.50.

Cullinan Therapeutics Stock Down 1.4 %

NASDAQ:CGEM opened at $10.21 on Friday. Cullinan Therapeutics has a 52 week low of $9.50 and a 52 week high of $30.19. The company has a market capitalization of $594.53 million, a P/E ratio of -3.60 and a beta of -0.16. The stock’s fifty day moving average is $11.42 and its two-hundred day moving average is $14.90.

Institutional Investors Weigh In On Cullinan Therapeutics

Several large investors have recently bought and sold shares of CGEM. Amalgamated Bank increased its holdings in Cullinan Therapeutics by 97.3% during the 3rd quarter. Amalgamated Bank now owns 1,768 shares of the company’s stock worth $30,000 after purchasing an additional 872 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new stake in Cullinan Therapeutics during the 4th quarter worth about $136,000. China Universal Asset Management Co. Ltd. increased its holdings in Cullinan Therapeutics by 10.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,346 shares of the company’s stock worth $150,000 after purchasing an additional 1,195 shares during the period. New York State Common Retirement Fund increased its holdings in Cullinan Therapeutics by 32.9% during the 4th quarter. New York State Common Retirement Fund now owns 12,918 shares of the company’s stock worth $157,000 after purchasing an additional 3,200 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in Cullinan Therapeutics during the 2nd quarter worth about $186,000. Hedge funds and other institutional investors own 86.31% of the company’s stock.

Insider Activity at Cullinan Therapeutics

In related news, CEO Nadim Ahmed sold 8,400 shares of the business’s stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $11.87, for a total value of $99,708.00. Following the sale, the chief executive officer now owns 263,150 shares in the company, valued at approximately $3,123,590.50. The trade was a 3.09 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jennifer Michaelson sold 4,693 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $11.41, for a total value of $53,547.13. Following the completion of the sale, the insider now owns 99,760 shares in the company, valued at $1,138,261.60. This represents a 4.49 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,582 shares of company stock worth $246,977. 6.07% of the stock is currently owned by company insiders.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.